PSA-Oxyntomodulin: Phase I started

Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of PSA-Oxyntomodulin in 12 healthy volunteers. Xenetic (formerly Lipoxen plc) has rights to devel...